BACKGROUND AND PURPOSE: The assessment of any health care intervention should consider both risks and benefits and take patients' preferences about these into account. The study reported in this paper aimed to elicit patient valuations of health states relevant to assessment of the prevention of stroke by warfarin anticoagulation therapy for patients with atrial fibrillation. METHODS: A sample of patients over the age of 60 years with atrial fibrillation from three family practices in North-East England was interviewed. Their health state values were elicited using the standard gamble method for general practitioner (GP)-managed warfarin treatment, hospital-managed warfarin treatment, major bleed, mild stroke and severe stroke. RESULTS: Of 180 patients, 69 (38%) agreed to participate, of whom 57 (83%) completed interviews. Median (mean) utility values were for GP-managed warfarin treatment 0.986 (0.948), hospital-managed warfarin treatment 0.984 (0.941), major bleed 0.880 (0.841), mild stroke 0.675 (0.641) and severe stroke 0 (0.189). There was wide variation in values between patients and the distributions were highly skewed. CONCLUSIONS: The results are of value in applying decision analysis to groups of patients. They should be used with caution in reaching decisions about appropriate treatment for individual patients, but may provide a starting point for necessary further exploration of those patients' individual preferences.
BACKGROUND AND PURPOSE: The assessment of any health care intervention should consider both risks and benefits and take patients' preferences about these into account. The study reported in this paper aimed to elicit patient valuations of health states relevant to assessment of the prevention of stroke by warfarin anticoagulation therapy for patients with atrial fibrillation. METHODS: A sample of patients over the age of 60 years with atrial fibrillation from three family practices in North-East England was interviewed. Their health state values were elicited using the standard gamble method for general practitioner (GP)-managed warfarin treatment, hospital-managed warfarin treatment, major bleed, mild stroke and severe stroke. RESULTS: Of 180 patients, 69 (38%) agreed to participate, of whom 57 (83%) completed interviews. Median (mean) utility values were for GP-managed warfarin treatment 0.986 (0.948), hospital-managed warfarin treatment 0.984 (0.941), major bleed 0.880 (0.841), mild stroke 0.675 (0.641) and severe stroke 0 (0.189). There was wide variation in values between patients and the distributions were highly skewed. CONCLUSIONS: The results are of value in applying decision analysis to groups of patients. They should be used with caution in reaching decisions about appropriate treatment for individual patients, but may provide a starting point for necessary further exploration of those patients' individual preferences.
Authors: Abdullah Pandor; Daniel Horner; Sarah Davis; Steve Goodacre; John W Stevens; Mark Clowes; Beverley J Hunt; Tim Nokes; Jonathan Keenan; Kerstin de Wit Journal: Health Technol Assess Date: 2019-12 Impact factor: 4.014
Authors: Mark H Eckman; Ruth E Wise; Katherine Naylor; Lora Arduser; Gregory Y H Lip; Brett Kissela; Matthew Flaherty; Dawn Kleindorfer; Faisal Khan; Daniel P Schauer; John Kues; Alexandru Costea Journal: Curr Med Res Opin Date: 2015-03-13 Impact factor: 2.580
Authors: Pablo Alonso-Coello; Victor M Montori; Ivan Solà; Holger J Schünemann; Philipe Devereaux; Cathy Charles; Mercè Roura; M Gloria Díaz; Juan Carlos Souto; Rafael Alonso; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ana Isabel Diez; Ignasi Gich; Gordon Guyatt Journal: BMC Health Serv Res Date: 2008-10-27 Impact factor: 2.655
Authors: Joris Kleintjens; Xiao Li; Steven Simoens; Vincent Thijs; Marnix Goethals; Ernst R Rietzschel; Yumi Asukai; Ömer Saka; Thomas Evers; Petra Faes; Stefaan Vansieleghem; Mimi De Ruyck Journal: Pharmacoeconomics Date: 2013-10 Impact factor: 4.981